|
Home
Search
Study Topics
Glossary
|
![]() |
![]() |
|
![]() |
|
![]() |
|
![]() |
![]() |
![]() |
|
![]() |
![]() |
||||||||||||||||||||||||||||||||||||
| Sponsor: | Leiden University Medical Center |
|---|---|
| Information provided by: | Leiden University Medical Center |
| ClinicalTrials.gov Identifier: | NCT01361295 |
Purpose
Radiofrequency catheter ablation of atrial fibrillation (AF) induces a procoagulant state, which leads to an acute risk for symptomatic cerebral embolism (CE) of approximately 1%. The induction of a procoagulant state has been studied in pulmonary vein isolation (PVI) with a non-cooled tip catheter. The induction of a procoagulant state using a cooled-tip catheter or a cryocatheter has not been studied yet. Due to the avoidance of high endocardial temperatures, it can be expected that these procedures induce a lower level of procoagulation.
Recent studies showed an 11% incidence of CE on diffusion weighted (DW) MRI in patients undergoing cooled-tip catheter ablation of AF. In the LUMC, three different catheters are currently being used: the cooled-tip catheter, the PVAC catheter and the cryocatheter. Since the PVAC catheter is equipped with non-cooled electrodes, the risk of endothelial scarring, local thrombosis and CE may be increased.
The goal of this study is to determine the effect of three different ablation catheters on the induction of a procoagulant state and the incidence of CE on DW-MRI in patients with AF undergoing PVI.
Our hypothesis is that patients with AF undergoing PVI using the PVAC catheter will show a higher rise in procoagulation and a higher incidence of CE on DW-MRI than patients with AF undergoing PVI with the cooled-tip catheter.
Patients with AF undergoing PVI using the cryocatheter will show a lower rise in procoagulation and a lower incidence of CE on DW-MRI than patients with AF undergoing PVI with the cooled-tip catheter.
| Condition | Intervention |
|---|---|
|
Atrial Fibrillation |
Procedure: Cryo-PVI Procedure: PVI with PVAC Procedure: PVI with Cooled-RF |
| Study Type: | Interventional |
| Study Design: | Allocation: Randomized Endpoint Classification: Safety/Efficacy Study Intervention Model: Parallel Assignment Masking: Single Blind (Outcomes Assessor) Primary Purpose: Treatment |
| Official Title: | The Occurrence of Cerebral Embolism (CE) in Catheter Ablation of Atrial Fibrillation (AF) Using Three Different Ablation Catheters |
| Estimated Enrollment: | 270 |
| Study Start Date: | April 2011 |
| Estimated Study Completion Date: | April 2014 |
| Estimated Primary Completion Date: | April 2014 (Final data collection date for primary outcome measure) |
| Arms | Assigned Interventions |
|---|---|
| Active Comparator: PVAC catheter |
Procedure: PVI with PVAC
Pulmonary vein isolation using the Medtronic PVAC catheter
Other Name: Ablation Frontiers
|
| Active Comparator: Cryoballoon catheter |
Procedure: Cryo-PVI
Pulmonary vein isolation using the Medtronic Arctic-Front balloon 28 or 23 mm
Other Name: Cryocath
|
| Active Comparator: Cooled-RF catheter |
Procedure: PVI with Cooled-RF
Pulmonary vein isolation using the Biosense Webster Navistar Thermocool catheter
Other Name: CARTO3 system
|
A total of 270 patients scheduled for a first ablation of paroxysmal AF will be included. Patients will be 1:1:1 randomized to PVI using the PVAC catheter, the cryoballoon catheter or the cooled-tip catheter.
Before the procedure, the procoagulant state will be assessed by measuring several markers of endothelial damage, activated coagulation, fibrinolysis and by measurement of fibrinogen and thrombin generation. Measurements will be repeated during and after the procedure.
Documentation of the formation of CE will be established by performing a DW-MRI before and after the ablation. The proportion of symptomatic CE will be quantified by neuropsychological tests and questionnaires.
Finally, transcranial doppler will be performed during the entire procedure to quantify the number and pattern of cerebral microembolic signals (MES).
Eligibility| Ages Eligible for Study: | 18 Years and older |
| Genders Eligible for Study: | Both |
| Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Exclusion Criteria:
Contacts and Locations| Netherlands | |
| Leiden University Medical Center | |
| Leiden, Zuid-Holland, Netherlands | |
| Principal Investigator: | Serge A. Trines, MD, PhD | Cardiology, LUMC |
More Information
| Responsible Party: | S.A.I.P. Trines, MD, PhD, LUMC |
| ClinicalTrials.gov Identifier: | NCT01361295 History of Changes |
| Other Study ID Numbers: | CE-AF-002 |
| Study First Received: | May 20, 2011 |
| Last Updated: | May 25, 2011 |
| Health Authority: | Netherlands: Medical Ethics Review Committee (METC) |
|
Atrial fibrillation cerebral embolism catheter ablation |
|
Atrial Fibrillation Intracranial Embolism Embolism Arrhythmias, Cardiac Heart Diseases Cardiovascular Diseases Pathologic Processes Intracranial Embolism and Thrombosis |
Cerebrovascular Disorders Brain Diseases Central Nervous System Diseases Nervous System Diseases Vascular Diseases Thromboembolism Embolism and Thrombosis Thrombosis |